Unlock the potential of next-generation sequencing

Impactful discoveries powered by NGS

Next-generation sequencing (NGS) can deliver unprecedented insights, unraveling the intricacies of the genome and transcriptome in biomarker research, gene expression studies, viral epidemiology and disease surveillance, as well as comprehensive genomic profiling to identify variants implicated in cancer and other diseases. However, challenges such as workflow optimization, customization and data analysis and interpretation can hinder progress. Partner with QIAGEN to unlock the full potential of NGS with innovative QIAseq technologies.

High-throughput genomic surveillance of emerging SARS-CoV-2 Alpha and Beta variants

The emergence of new, highly transmissible SARS-CoV-2 variants has elevated the need for high-throughput whole viral genome sequencing to accelerate genomic surveillance efforts. Cataloging new variants and evaluating the impact of the accumulated mutations is critical for vaccine development and effective public health measures. Explore how our high-performance, scalable NGS workflows with integrated bioinformatics facilitate accurate SARS-CoV-2 variant detection and phylogeographic tracking.

Go from RNA-seq to gene expression insights with ease

Struggling to make sense of your RNA-seq data? Take the stress out of data analysis and fast-track your path to gene expression insights with the new RNA-seq Analysis Portal. Designed for biologists and fully integrated with GeneGlobe, this intuitive, web-based solution is now included with QIAseq RNA-seq and miRNA-seq kits. Simply upload your sequence files into the RNA-seq Analysis Portal, start your analysis and go from FASTQ files to focused insights into the top 10 canonical pathways, upstream regulators and diseases using powerful IPA knowledge bases.

Expanding disease insights with exome sequencing

The coding portion of the genome holds tantalizing information on multiple diseases. Unlocking these details through exome sequencing can reveal powerful insights into disease-associated variants. However, coverage issues, long turnaround times and data analysis bottlenecks can diminish progress. Explore a time-saving workflow that seamlessly combines uniform exome coverage with streamlined secondary analysis, rapid variant filtering and annotation.